Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18387)	4/1/1998 12:07:00 AM
From: celeryroot.com	Respond to of 32384

SRGN has a very strange graph today, check Lombard

To: Henry Niman who wrote (18387)	4/1/1998 12:12:00 AM
From: WTDEC	Respond to of 32384

Henry and Celeryroot, here is another item from a recent SRGN release. It seems like at least one of their key researchers is headed for 'greener' pastures, which lends weight to a buyout. "DiagnoCure Inc. today announced the signing of a licensing agreement with Seragen Inc. [OTC BB:SRGN - news], a biotechnology company based in the Boston area, as well as a collaborative research and consultation agreement with Dr John Murphy, one of Seragen's founders and a world authority in the field of protein engineering. " Regards, Walter